


US ; Left Breast



-0

-

-1

-

-2


-

-3

-

-4

cm



穿刺吸引細胞診



Pap.



HE



PAS




Giemsa




Pap.
集細胞处理

乳房針生檢病理組織標本




HE

Pap.x100




100 μ m

Pap.x100




100 μ m

Pap.x400



20 μ m

Pap.x200



50 μm


HE染色標本→免疫染色用ブロックを選択



Ag




見たいトコから欠けたりなくな...(T-T)




HEx40

200 μ m




Agx40

200 μ m




HE + Ag(不透明度60%)

200 μ m




HEX100

100 μm




HEx40

200 μ m




HEX100

100 μm




HEx200



50 μ m



Pap.x100





Pap.x200




Pap.x400

MRI Tumor






MRI LNs





PET-CT




穿刺吸引細胞診及び病理組織生検にて、
Carcinoma, high grade malignancyと診断、
CT他、画像上、傍胸骨、鎖骨上リンパ節転移の疑い。
既往歴；一昨年、脳梗塞にて3ヶ月入院
家族歴；乳癌、卵巣癌、前立腺癌、胃癌
問題点；組織診断

配布標本は左乳房切除術標本、
同時提出されたリンパ節27個全てに転移あり。
Mappingで8.6×3×3 cm,
pT3N3a(sc), stage III B。
腫瘍細胞はMIB-1 index 80%以上、
HER2, EsR, ProR, いずれも陰性

Lt Breast ; 17.1×11.1×5.2 cm

Lt Upper



10

20


30

40


50

Lt Breast ; 17.1×11.1×5.2 cm

→ Lt Upper




Tumor ; 8.6×3×3 cm
(on Mapping) pT3






LN level 3





LN SC




LN level 2




LN level 1




N3a(sc) (27/27)



送付標本→1417





最大充実部→検索





送付標本→1417

最大充実部→検索






送付標本→1417


最大充実部→検索



送付標本→1417


最大充実部→検索






#43(1417) ; HEx20

500 μ m



#43(1417) ; HEx20

500 μ m




#53 ; HEx20

500 μ m




#53 ; Agx20

500 μ m




#53 ; HE+Ag






#53 ; HEx40

200 μ m



#53 ; HE+Ag






#53 ; HE+Agx100


1000 μ m

1000 μ m




HEx200

50 μ m




HEx200

50 μ m




HEx200

50 μm




SMA

50 μm




SMA

50 μm




SMA

50 μm




AE1/3

50 μ m



AE1/3

50 μ m





AE1/3


50 μ m

免疫染色結果


	16-13(NB)	16-98-53(O)T	16-98-17(O)LN
MIB-1 index	≥80%	≥80%	≥80%
HER-2	(-)	(-)	(-)
EsR	UD	(-)	(-)
ProR	UD	(-)	(-)
Keratin-AE1/3	(+)	(+)	
CEA	(-)		
CK7	p(+)	(+)	
CK20	(-)	(-)	
CGA	(-)	(-)	
CD56	UD	(-)	
Vimentin	(-)		
αSMA	(-)	p(+)	p(+)
S-100	(-)	(-)	
TTF-1	(-)	(-)	
CD10		(-)	(-)
Synapto.		(-)	




Myoepithelial Carcinoma ?



AE1/3



SMA



Giemsa x400

20 μ m